Novel therapies for the prevention of stroke (Q28210724)

Expert Opinion on Investigational Drugs

Europe PubMed Central

title

Novel therapies for the prevention of stroke (English)

0 references

2

Gregory Y H Lip

0 references

author name string

Christopher J Boos

series ordinal

1

0 references

language of work or name

English

0 references

publication date

December 2004

0 references

published in

0 references

volume

13

0 references

issue

12

0 references

page(s)

1615-30

0 references

cites work

Preventing stroke in patients with atrial fibrillation: current treatments and new concepts

1 reference

https://api.crossref.org/works/10.1517/13543784.13.12.1615

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.13.12.1615

Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.13.12.1615

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.13.12.1615

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.13.12.1615

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.13.12.1615

Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.13.12.1615

Plasma levels of nitric oxide and related vasoactive factors following long-term treatment with angiotensin-converting enzyme inhibitor in patients with essential hypertension

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.13.12.1615

Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.13.12.1615

Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.13.12.1615

Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.13.12.1615

An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.13.12.1615

A strategy to reduce cardiovascular disease by more than 80%

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.13.12.1615

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Stroke incidence and case fatality in Australasia. A comparison of the Auckland and Perth population-based stroke registers.

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Predicting survival for 1 year among different subtypes of stroke. Results from the Perth Community Stroke Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Long-term risk of first recurrent stroke in the Perth Community Stroke Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Further evolution toward effective therapy for acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Public perception of stroke warning signs and knowledge of potential risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The fiamingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Risk factors for intracranial hemorrhage in outpatients taking warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Biochemistry and clinical pharmacology of new anticoagulant agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Management of venous thromboembolism: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Short- and long-acting synthetic pentasaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Aspirin as an antiplatelet drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Pathophysiologic and therapeutic importance of tissue ACE: a consensus report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Pharmacological modulation of platelet function in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Pleiotropic effects of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Assessing possible hazards of reducing serum cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

New drugs for the treatment of hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

NK-104: a novel synthetic HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Ezetimibe: A Selective Cholesterol Absorption Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Ezetimibe: the first in a novel class of selective cholesterol-absorption inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Ezetimibe for management of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Meta-analysis of observational studies on fish intake and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Fish consumption and coronary heart disease mortality. A systematic review of prospective cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Long-term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Fish oil prevents insulin resistance induced by high-fat feeding in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Stroke in the diabetic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Fish consumption and mortality from all causes, ischemic heart disease, and stroke: an ecological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Fish consumption and cardiovascular disease in the physicians' health study: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Fish consumption and risk of stroke. The Zutphen Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Hyperhomocysteinemia: a million ways to lose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Oxidant stress: a key determinant of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Mild hyperhomocysteinemia is a risk-factor in all etiological subtypes of stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615

Changes in stroke incidence and case-fatality in Auckland, New Zealand, 1981-91

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.12.1615